We would love to hear your thoughts about our site and services, please take our survey here.
I've been waiting for a moment to buy (=price to go down) but was prompted to action after seeing this tweet.
https://twitter.com/maijahollmen/status/1400083829394661377?s=20
I have not followed the latest developments closely so this may be old news and already priced in.
I'm so in love with this stock. So much promise and positivity. Happy to wait for another 6-9 months and I shall top up if an opportunity presents itself.
Well, that was a nice interview. Markku looked more rested, even relaxed. In his couple of previous presentations he came across super tired so much so that it was difficult to understand what he was saying. I took it then as a positive sign at him being busy working with the US people getting everything up and running. Nice to see that he has managed to catch up with his sleep.
This was defo much needed confidence boost. Looks like Faron is not rushing into any deals so they must know the value of the data to come. I do like how he is passionate about the science. Felt like if the presenter had not repeatedly prompted him to talk about the business side he would have just happily talked about test data and molecules! That's why I feel he is an authentic and genuine person. He seems better scientist than stock market spinner and that is understandably frustrating to anyone who has fully loaded position and impatiently waiting for the share price to rocket to the new heights.
GLA!
Pickled this up from Maija's twitter feed.
Apologies if not relevant for us.
https://www.frontiersin.org/articles/10.3389/fimmu.2021.602122/full
I'm glad I'm the the only one having positive vibes about Nokia...
https://youtu.be/XbN44t2z6Oo
So far I have only been given what I was entitled to. No spares for me yet. Only requested additional 600 shares or so. I'm with HL.
Any thoughts?
Faron Pharmaceuticals Oy
("Faron" or the "Company")
Exercise of options
Issue of equity
Company announcement, 24 September 2020 at 9.15 (EEST)
TURKU, FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, announces that it has received notifications from option holders to exercise D options over 15,000 ordinary shares in the Company at an exercise price of EUR 1.09 (approx. GBP 1.00) per share under the Company's 2015 Option Plan ("New Ordinary Shares"). The terms and conditions of the 2015 Option Plan are available on the Company's website at https://www.faron.com/sites/default/files/Option%20Plan%202015_Terms%20and%20Conditions_20200518.pdf.
Applications will be made to the London Stock Exchange and Nasdaq Helsinki to admit the New Ordinary Shares to trading on AIM and Nasdaq First North Growth Market, respectively. Admission of the New Ordinary Shares is expected to occur on or around 5 October 2020 following issue and registration of the New Ordinary Shares on or around 2 October 2020 ("Registration"). The New Ordinary Shares will rank pari passu with existing ordinary shares.
Faron's enlarged issued number of shares immediately following Registration will be 46,814,747 ordinary shares with voting rights attached. The Company has no shares in treasury; therefore upon, and subject to, Registration, the total number of voting rights in Faron will be 46,814,747. This figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify an interest in, or a change to their interest in, the issued shares and votes of the Company.
For more information please contact:
Faron Pharmaceuticals Oy
Dr Markku Jalkanen, Chief Executive Officer
investor.relations@faron.com
I'd say sells.